Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial
- Sponsor
- Qingdao Central Hospital
- Study ID
- NCT05392257
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Overall Survival
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab + zanubrutinib + lenalidomide — DRUGRituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
Study Details
This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B cell lymphoma.
Key Dates
- Start date
- May 1, 2022
- Status verified
- May 2022
- Primary completion
- May 1, 2024
- Completion
- May 1, 2024
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Arms
Primary Outcome Measure
The overall survival in this population of patients [ Time Frame: 24 months ]
Related Studies
- Long-term Follow-up of Subjects Treated With CAR T CellsRecruiting · Marcela V. Maus, M.D.,Ph.D. · Boston, Massachusetts